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Abstract
Background: Acute uncomplicated cystitis (AUC) is an ideal target of optimization for antibiotic therapy in primary
care. Because surveillance networks on urinary tract infections (UTI) mix complicated and uncomplicated UTI,
reliable epidemiological data on AUC lack. Whether the antibiotic choice should be guided by a rapid urine test
(RUT) for leukocytes and nitrites has not been extensively studied in daily practice. The aim of this primary care
study was to investigate local epidemiology and RUT-daily use to determine the optimal strategy.
Methods: General practitioners included 18–65 years women with symptoms of AUC, performed a RUT and sent
urines for analysis at a central laboratory. Different treatment strategies were simulated based on RUT and
resistance results.
Results: Among 347 enrolled patients, 78% had a positive urine culture. Escherichia coli predominated (71%) with
high rates of susceptibility to nitrofurantoin (100%), fosfomycin (99%), ofloxacin (97%), and even pivmecillinam
(87%) and trimethoprim-sulfamethoxazole (87%). Modelization showed that the systematic use of RUT would reduce
by 10% the number of patients treated. Fosfomycin for patients with positive RUT offered a 90% overall bacterial
coverage, compared to 98% for nitrofurantoin. 95% for ofloxacin, 86% for trimethoprim-sulfamethoxazole and 78%
for pivmecillinam.
Conclusion: Local epidemiology surveillance data not biased by complicated UTI demonstrates that the worldwide
increase in antibiotic resistance has not affected AUC yet. Fosfomycin first line in all patients with positive RUT
seems the best treatment strategy for AUC, combining good bacterial coverage with expected low toxicity and
limited effect on fecal flora.
Trial registration: The current study was registered at clinicaltrials.gov (NCT00958295)
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Background
The emergence of multidrug resistant Enterobacteriaceae
in the community reinforces the need to reduce antibiotic
prescription, particularly for molecules at high risk of eco-
logical effect such as broad spectrum beta-lactams and
quinolones. Given its benign nature, acute uncomplicated
cystitis (AUC) is an ideal target of action. Rapid urine test
(RUT) for detection of nitrites and leucocytes have a high
negative predictive value, so that some guidelines on AUC
recommend their systematic use, such as the French [1],
the Scottish [2] and that of the European Association of
Urology [3]. Of note, diagnostic procedures are not ad-
dressed by the current IDSA and ESCMID guidelines
[1,4]. To spare beta-lactams and quinolones, it is now rec-
ommended worldwide to treat AUC with nitrofurantoin,
trimethoprim-sulfamethoxazole (TMP-SMX), fosfomycin
or pivmecillinam, depending on local community resist-
ance prevalence [1,4]. Unfortunately, as underlined by the
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IDSA and ESCMID guidelines, local epidemiological data
on AUC lack, and surveillance networks mix complicated
and uncomplicated urinary tract infection (UTI) [5]. In
France, fosfomycin is the only drug recommended first
line for AUC; because of its poor efficacy against Staphylo-
coccus saprophyticus, it is suggested, but with a low level
of evidence, that patients under 30 years (at higher risk of
S. saprophyticus infection) and with negative nitrite detec-
tion should be treated with nitrofurantoin or quinolones.
Thus, the current study was performed to evaluate the
current epidemiology of AUC, the contribution of RUT in
a primary care practice, and to compare different treat-
ment strategies.
Methods
Patients and ethical issues
Patients were enrolled from 2009 to 2011, a network of
French general practitioners (GPs). Patients included were
those routinely diagnosed AUC in primary care, and had
the following inclusion criteria: female gender, age be-
tween 18 and 65 years, and pain on urination, pollakiuria,
urgency, or supra-pubic pain. Patients with complicated
or recurrent cystitis or pyelonephritis were excluded.
Thus, urinary tract disorders (such as renal failure, lithia-
sis, reflux, urinary catheter etc.), diabetes, immune deficit,
cancer, recurrent urinary tract infections (≥3 episodes in
the previous year), and pregnancy were causes of exclu-
sion. Patients with fever or flank pain were also excluded.
All the patients meeting the inclusion criteria gave in-
formed consent. For each patient included, the GP received
an honorarium equivalent to the cost of a consultation (21
Euros) to compensate for the time needed for the study.
The study was approved by the local protection committee
(CPP-SC 2009/003), and registered at clinicaltrials.gov
(NCT00958295) and funded by Rouen University Hospital.
Urine analysis
At the GP’s office, a midstream urine sample was col-
lected after perineal cleansing, using the BD Vacutainer®
urine collection and transport medium kit. RUT, to de-
tect leukocytes and nitrites (Bayer multistix®), was imme-
diately performed by the GP.
The urine sample was then analyzed within 48 hours at
the Rouen University Hospital laboratory according to
French recommendations [6-10]. Significant threshold
was >104/mL for leukocyte count. Two threshold were
used for bacterial count after urine culture: (a) “stand-
ard thresholds”, i.e., those of the current French guide-
lines ≥103 CFU/mL for Enterobacteriacae and S.
saprophyticus, ≥105 CFU/mL for other pathogens [1,11];
(b) and “reduced thresholds”, used in other studies on
AUC: ≥102 CFU/mL for Enterobacteriacae and S. sapro-
phyticus, ≥104 CFU/mL for other pathogens [4,6,8-22].
Urine cultures growing more than two bacteria were
considered contaminated. Pathogens were identified based
on their biochemical reaction according to the API system
(BioMerieux®, La Balme les grottes, France). Susceptibility
testing was performed by disk diffusion method and strains
were classified as susceptible, intermediate, or resistant ac-
cording to French recommendations [1,4,12,23-25].
Results of urine analysis were sent to GP only on re-
quest since urine analysis is recommended in France
only in case of failure of the probabilistic treatment.
Antibiotic strategies
The GP decided whether to prescribe antibiotics or not,
based on its own judgment (no recommendations in the
study protocol).
To analyze the contribution of RUT to the antibiotic de-
cision, different antibiotic strategies were modelized for
the total cohort, based on RUT and culture results. The
first strategy evaluated administration of fosfomycin,
nitrofurantoin, TMP-SMX, pivmecillinam or ofloxacin to
all patients (i.e., no RUT used). The second strategy evalu-
ated different antibiotic treatments solely in patients with
leukocyte or nitrite positive RUT. The antibiotic choice
could be fosfomycin, TMP-SMX, or pivmecillinam in all
cases; alternatively, fosfomycin could be indicated for all
cases, excepted women <30 years with negative nitrite de-
tection by RUT for which nitrofurantoin or ofloxacin were
preferred.
For each treatment strategy, three parameters were es-
timated: (1) the rate of patients treated with antibiotics;
(2) the rate of appropriate decisions to prescribe antibi-
otics or not: the decision was qualified appropriate when
the GP prescribed antibiotics to a patient with positive
urine culture or did not prescribe antibiotics to a patient
with negative culture; conversely, the decision was quali-
fied inappropriate when the GP prescribed antibiotics to
a patient with negative culture or did not prescribe anti-
biotics to a patient with positive culture; (3) the overall
rate of bacterial coverage, measured only in patients
with AUC confirmed by urine culture, and depending on
distribution of pathogens and their resistance rates.
Statistical methods
The results were analyzed per protocol, described by their
mean value and standard deviation, or by frequency.
Quantitative data were compared using the Fisher exact
t test. A p value <0.05 was considered significant.
Results
Population
A total of 362 patients were included, but 15 patients were
excluded for recurrent cystitis (n = 3), delays in transporta-
tion to the laboratory (n = 11), or both (1). Mean age was
38 years with two peaks of incidence, women aged 18 to
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29 years and 42 to 53 years accounting for 32% and 38%
respectively of the cohort.
Rapid urine test for detection of leukocytes and nitrites
RUT was performed in all 347 cases, detecting leuko-
cytes (L) in 302 (87%), and nitrites (N) in 81 cases (23%),
with the following results: L + N + = 74 (21%), L-N- = 37
(11%), L-N + = 7 (2%), L + N- = 229 (66%).
Urine analysis
Table 1 shows the results and leukocyte counts and bac-
terial cultures. For 27 patients (8%), no significant leuko-
cytes and no significant bacteriuria were observed.
Significant leukocyte concentration in urine was observed
in 305 patients (88%). With standard thresholds, 199
(57%) cultures were positive for 1 (n = 194) or 2 pathogens
(n = 5). With reduced thresholds, 272 (78%) cultures were
positive for 1 (n = 266) or 2 (n = 6) pathogens. Only 33
urine cultures (9.5%) had no visible growth. Among the
pathogens isolated Escherichia coli dominated (n = 157,
77%) while S. saprophyticus was at the second rank (n =
14, 7%) followed by Proteus spp (n = 10, 5%), Enterococcus
spp (n = 9, 4.4%), Klebsiella spp (n = 5, 2.5%), Enterobacter
spp (n = 5, 2.5%), and Citrobacter spp (1), Streptococcus
spp (1) and S. aureus (1). Among the 14 patients with S.
saprophyticus infection, eight (57%) were less than 30 years
old. No significant change was observed in overall distri-
bution of the species analyzed when reduced thresholds
were considered.
Table 2 describes the epidemiology of resistance for E.
coli, all Gram negative, all Gram positive, and for all
pathogens together. Globally, an extremely low rate of re-
sistance was observed. In particular, no extended-
spectrum beta-lactamase (ESBL) producing enterobacteria
and no multi-drug resistant organisms were isolated.
Among E. coli isolates, only one strain expressed a cepha-
losporinase, and a very low rate of quinolone resistance
was observed (ofloxacin resistance: 2%), even at a low-
level (nalidixic acid resistance: 3%). The most common E.
coli resistance phenotypes were wild type (56%), amoxicil-
lin resistance (27%), or amoxicillin + TMP-SMX resistance
(12%). Overall susceptibility rates of the isolated patho-
gens were above 85% for the antibiotic regimen most
commonly used to treat AUC: fosfomycin, nitrofuran-
toin, TMP-SMX, or fluoroquinolones, and 75% for
pivmecillinam.
Table 1 Results of the rapid urine test (RUT) performed by the general practitioner compared to urine analysis at the
central laboratory
RUT results Urine analysis
Leukocyturiaa Bacteriuria
at standard thresholdsb at reduced thresholdsc
L+ / N + (n = 74) 73 (99%) 61 (82%) 70 (95%)
58 Enterobacteriaceae 62 Enterobacteriaceae
3 S. saprophyticus 4 S. saprophyticus
5 miscellaneous
L- / N- (n = 37) 9 (24%) 3 (8%) 6 (16%)
3 Enterobacteriaceae 6 Enterobacteriaceae
2 miscellaneous
L+ / N- (n = 229) 216 (94%) 128 (56%) 189 (83%)
114 Enterobacteriaceae 162 Enterobacteriaceae
9 S. saprophyticus 11 S. saprophyticus
9 miscellaneous 18 miscellaneous
L- / N + (n = 7) 7 (100%) 7 (100%) 7 (100%)
6 Enterobacteriaceae 6 Enterobacteriaceae
2 S. saprophyticus 2 S. saprophyticus
2 miscellaneous
Total (n = 347) 305 (88%) 199 (57%) 272 (78%)
178 Enterobacteriaceae (89%) 236 Enterobacteriaceae (85%)
14 S. saprophyticus (7%) 17 S. saprophyticus (6%)
11 miscellaneous (5%) 25 miscellaneous (9%)
aLeukocyturia >104/mL considered significant.
bStandard thresholds: ≥103 CFU/mL for Enterobacteriaceae and S. saprophyticus, ≥105 CFU/mL for other pathogens.
cReduced thresholds: ≥102 CFU/mL for Enterobacteriaceae and S. saprophyticus, ≥104 CFU/mL for other pathogens.
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Antibiotic treatments
During the previous 6 months, 91 patients (26%) had re-
ceived antibiotics for any reason, either at one (n = 72,
79%), two (n = 14, 15%), or three occurrences (n = 5, 5%)
during an average of 6.7 days. No obvious correlation be-
tween previous exposure to antibiotics and resistance to
urine pathogen was observed. Of the 347 patients, 31 (9%)
were not treated with antibiotics. RUT was negative
for both leukocyte and nitrite detection for 25 of them,
negative for leukocytes in four patients, and negative
for nitrites in two patients. Of the 316 patients treated
with antibiotics, 148 (47%) had a bacteriuria below the
standard thresholds, and 94 patients (30%) below re-
duced thresholds. While French guidelines recom-
mend fosfomycin (single dose) as first-line, and
nitrofurantoin (5 days) or fluoroquinolones (≤3 days)
only as second-line treatment, GPs chose almost
equally fosfomycin (n = 150, 47%) and fluoroquino-
lones (n = 142, 45%), and rarely cefixim (n = 10, 3%),
nitrofurantoin (n = 8, 2.5%) or TMP-SMX (n = 6.2%).
Table 2 Antibiotic susceptibility of the pathogens isolated at standard thresholds from urine culture of acute
uncomplicated cystitis
Antibiotic Antibiotic susceptibilitya (%)
E. coli All Gram - All Gram + All pathogens
(n = 157) (n = 178) (n = 25) (n = 203)
Amoxicillin 63 56 32 /
Amox/clav 91 88 NTb /
Ticarcillin 64 61 NT /
Ticar/clav 92 92 NT /
Piperacillin 64 61 NT /
Pip/Taz 99 99 NT /
Pivmecillinam 87 88 NT 76c
Cefalotin 63 61 NT /
Cefotaxime 99 99 NT /
Ceftazidime 99 99 NT /
Cefepime 99 99 NT /
Imipenem/cilastatin 100 100 NT /
Gentamicin 99 99 57d /
Tobramycin 99 99 NT /
Amikacin 100 100 NT /
Netilmicin 99 99 NT /
TMP-SMX 87 87 63 85
Nalidix acid 97 87 NT /
Ofloxacin 97 99 59 94
Levofloxacin 97 99 95 98
Nitrofurantoin 100 92e 100 98
Fosfomycin 99 98 27 89
Fucidic acid NT NT 58 /
Erythromycin NT NT 17 /
Lincomycin NT NT 62 /
Pristinamycin NT NT 62 /
Rifampin NT NT 61 /
Vancomycin NT NT 100 /
aIntermediate strains considered resistant.
bNT: not tested.
cAll Gram +were considered resistant in vitro to pivmecillinam.
dNatural low level resistance of Streptococcus and Enterococcus spp considered non susceptible.
eProteus spp considered naturally resistant to nitrofurantoin.
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Diagnosis performance of RUT versus urine culture
Table 3 shows the performance of RUT compared to
urine culture with two different bacterial thresholds in
this population of female patients with symptoms sug-
gestive of AUC. RUT had a negative predictive value of
92% when standard thresholds were used, lessening to
84% with reduced thresholds. Hypothetically, had GPs
decided to treat only patients with leukocytes or nitrites
detected at RUT, 310 patients (89%) would have been
treated. Of these 310 patients, 115 patients (37%) would
not finally be diagnosed with AUC according to urine
culture at standard thresholds and 60 (19%) at reduced
thresholds. Of the 37 non treated patients (11%), 6 pa-
tients (16%) would finally be diagnosed with cystitis ac-
cording to urine culture at standard thresholds and 7
(19%) at reduced thresholds.
Of the 266 patients with leukocyte positive and nitrite
negative RUT, Enterobacteriaceae were isolated in 117
cases (44%), mostly with a concentration ≤103 CFU/mL
and S. saprophyticus was isolated in only 9 cases (3%). In
the subgroup of patients below 30 years of age (n = 90),
S. saprophyticus was isolated in only six of them (15%).
For detection of Enterobacteriaceae, nitrite detection by
RUT had 11% sensitivity, 93% specificity, 74% positive
predictive value, and 35% negative predictive value. RUT
performance in detecting Enterobacteriaceae was not
significantly affected by reduced diagnosis thresholds for
diagnosis in urine culture (data not shown).
Modelization of treatments
Table 4 details the results of the modelized treatment strat-
egies. Use of RUT to help GPs in decision-making regard-
ing antibiotic prescription lowered the number of patients
treated by 10%, and significantly improved the appropriate-
ness of antibiotic prescription (73% vs 80%, p = 0.02), re-
gardless of bacterial thresholds used. As expected, given
the low ability of RUT to predict S. saprophyticus infection,
nitrite-detection-based strategies did not improve overall
success rates. Whichever antibiotic strategy was simulated,
overall bacterial coverage rates exceeded 85% in all cases,
except in pivmecillinam-based strategies (≥76%). Even
TMP-SMX-based strategies had ≥85% presumed bacterial
coverage. Nitrofurantoin or fluoroquinolone-based strat-
egies had the highest rates of bacterial coverage, achieving
4 to 6% improvement on fosfomycin-based strategies.
Discussion
Three main messages can be learnt from this series per-
formed at the GP’s office in a strict “real-life” clinical set-
ting: (a) the rate of antibiotic resistance remains extremely
low in this specific population of female patients with non
recurrent AUC, so that fluoroquinolones, fosfomycin,
nitrofurantoin, TMP-SMX, and to a lesser extent pivmecil-
linam, offer excellent bacterial coverage; (b) the bacterial
thresholds retained in the guidelines for biological diagno-
sis derive from specific studies mainly on inpatients, and
might not fit daily care reality; (c) rapid urine test can re-
duce inappropriate antibiotic prescriptions by 10%, but
cannot accurately suspect S. saprophyticus infections.
From these results, we suggest that RUT and recent epi-
demiology data offer prescribers the rare opportunity both
to optimize and to reduce antibiotic prescription, hence
lowering risk of adverse ecological effects.
Optimal probabilistic antibiotic prescription requires
recent and detailed epidemiological data. In this series,
very few levels of resistance were observed (only 3% of
resistance to fluoroquinolone and 1% of resistance to
third generation cephalosporin for E. coli). Resistance
rates in our series are very similar to recent international
studies specifically devoted to AUC [1,4,26-31]. This can
probably be explained by the fact that women with non
recurrent AUC are otherwise healthy subjects, uncom-
monly exposed to antibiotics and thus to any ecological
adverse effect on their gut flora. Indeed only a quarter of
our patients had received antibiotics during the previous
six months, a rate twice lower than that of the general
population of 18–65 years old [32]. Our results markedly
differ from those of French and international surveil-
lance networks that reported during the same period re-
sistance for outpatient urinary E. coli isolates up to 14%
for fluoroquinolones and up to 5% for third generation
cephalosporin. These latter networks are biased, because
they include patient cohorts visiting urologists, or pa-
tients with recurrent or complicated UTI that have
Table 3 Performance of the rapid urine test for the diagnosis of AUC according to the bacterial concentration in urine
culture
Performance criteria Bacterial concentrations in urine cultures
≥ standard thresholdsa ≥ reduced thresholdsb
Sensitivity 98% 98%
Specificity 23% 33%
Positive predictive value 63% 79%
Negative predictive value 92% 84%
aStandard thresholds: ≥103 CFU/mL for Enterobacteriaceae and S. saprophyticus, ≥104 CFU/mL for other pathogens.
bReduced thresholds: ≥102 CFU/mL for Enterobacteriaceae and S. saprophyticus, ≥103 CFU/mL for other pathogens.
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higher antibiotic pretreatments hence are at higher risk
of multidrug resistance [1,6-10,33-35]. Hence global epi-
demiology data UTI should not be used to guide anti-
biotic choice for AUC.
The second prerequisite for improving the accuracy of
antibiotic prescription is using reliable diagnosis methods.
As for AUC diagnosis can rely on symptoms, RUT, or
urine analysis. Numerous studies have proposed scores
based on clinical symptoms and RUT, all of them using
urine analysis as the gold standard. In these studies the
pretest likelihood of infection increased RUT performance
[4,12-22]. In our study, since all patients were young fe-
males without comorbidities, consulting for symptoms
suggesting AUC, it was assumed that the probability of
AUC exceeded 80% when RUT detected nitrites or leuko-
cytes [1,4,12]. Using the standard bacterial thresholds
retained in French guidelines (≥103 CFU/mL for Entero-
bacteriaceae or S. saprophyticus, and ≥105 CFU/mL for
other pathogens), 148 (43%) patients did not have the bio-
logical criteria for diagnosis of AUC [1,4]. A high rate of
AUC differential diagnosis (e.g., vaginitis or urethritis) is
most unlikely, and we suspect that standard thresholds do
not fit reality. Indeed, standard thresholds have been de-
termined from morning concentrated urines [6-10],
whereas in our study as in daily life, urine was mostly col-
lected during daytime so that significant thresholds were
certainly lower. This explanation is supported by the high
rate of significant leukocyturia (82% of our patients) while
no visible growth was uncommon (only 9.5% of patients).
Using reduced thresholds for all pathogens, 247 urine ana-
lyses (71%) would have been positive, which is more con-
sistent with other studies. This debate on diagnosis
thresholds is crucial for evaluating RUT performances for
diagnosis of AUC. As a fact, depending on the diagnosis
thresholds used, the negative predictive value of RUT low-
ered from 92% to 84%. But, more meaningful for the pre-
scriber than the negative predictive value of RUT, may be
evaluation of the impact of RUT-based strategies on the
appropriateness of decision-making regarding antibiotic
prescription: if GPs had prescribed antibiotics only in pa-
tients with leukocyte or nitrite positive RUT, antibiotic
prescription would have been reduced by 10% and the ap-
propriateness of the decision improved, regardless of diag-
nosis thresholds used. Of those patients with biologically
confirmed AUC, only three to six out of 347 patients
would not have been treated with antibiotics, but, accord-
ing to data from the literature, up to three patients might
have been cured spontaneously, or all six patients could
Table 4 Evaluation of different treatment strategies based on local epidemiology and on the results of rapid urine test
(RUT) in a cohort of 346 patients with symptoms of acute uncomplicated cystitis
Antibiotic (ATB) Treatment strategy
ATB for all symptomatic
patients (i.e. no RUT used)
ATB only in patients
with positive RUTa
Patients treated (%) 347 (100) 311 (89)
Appropriate ATB decisionb (%) 253 (73) 278 (80)
0.02d
No ATB, negative UCc 0 31
ATB, positive UC 253 247
Inappropriate ATB decision (%) 94 (27%) 70 (20%)
ATB, negative UC 94 64
No ATB, positive UC 0 6






Fosfomycin, except if RUT-
For nitrites and age < 30: nitrofurantoin 93
Fosfomycin, except if RUT-
For nitrites and age < 30: ofloxacin 93
aRUT considered positive when leukocytes and/or nitrites were detected.
bATB decision considered appropriate or not according to the results of urine analysis.
cUC: urine culture.
dNB: p = 0.02 when appropriate and inappropriate ATB decision were compared using standard thresholds, and p = 0.03 using reduced thresholds.
eSusceptibility rate for patients with a positive urine culture.
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have consulted later with minimal risk of progression to
pyelonephritis [1,11]. RUT however cannot help in identi-
fying the causative pathogen. Contrary to French guideline
suggestions, RUT demonstrated low ability to discriminate
between Enterobacteriaceae and Gram positive pathogens,
since patients were more likely to have a Gram positive in-
fection when nitrite detection was positive than negative.
Even taking into account the subgroup of patients
below 30 years old, in which prevalence of S. saprophy-
ticus is higher, Gram positive only represented 15% of
patients. Thus, we recommend that the diagnosis
thresholds retained in urine analysis be tempered, and
that RUT be used to limit inappropriate antibiotic pre-
scriptions, not to anticipate microbiological diagnosis.
As a consequence of the low resistance rates, bacterial
coverage rate was high for all antibiotics evaluated, with
only a slight superiority for nitrofurantoin or fluoroqui-
nolones. Bacterial coverage rate can only be cautiously
considered as an indirect, and probably underestimated
evaluation of the cure rate of antibiotic treatment for
AUC, because of spontaneous cure in up to 40% of un-
treated patients, and because of high antibiotic urine
concentrations that may lead to cure despite in vitro re-
sistance [6,8-11]. However, bacterial coverage rate might
be accurate for comparing antibiotic regimen such as
nitrofurantoin and fosfomycin which demonstrated simi-
lar clinical and microbiological efficacy on susceptible
strains in previous studies [23-25]. In our study, both
molecules exhibited high (≥95%) and similar rates of
bacterial coverage. Pivmecillinam had the lowest rate of
bacterial coverage, estimated by in vitro susceptibility
data, because Gram positive are considered naturally re-
sistant. Nevertheless, several clinical studies have dem-
onstrated up to 93% clinical cure rate in S. saprophyticus
AUC because of high pivmecillnam concentration in
urine [26-31]. If pivmecillinam had been considered ac-
tive in vivo on S. saprophyticus infections, the estimated
success rates of pivmecillinam treatments would have
reached 81% in our series.
Since all simulated antibiotic strategies appeared highly
effective, priority should be given to the risk of adverse ef-
fects, including ecological damage. Among the for antibi-
otics currently recommended the 2010 IDSA and ESCMID
guidelines, we consider that fosfomycin has the best benefit-
risk balance, at the individual and collective levels; pivmecil-
linam though well tolerated requires a heavier regimen (bid
for 3–5 days) for potentially a lower efficacy; TMP-SMX
causes early and sustained ecological damage as well as rare
but serious toxicity [36]; nitrofurantoïn is proposed first-line
by many countries, because of good coverage rate and low
ecological pressure. Because severe adverse effects such as
allergic pneumonia or hepatitis and neuropathy have rarely
been described even after a very short course, we suggest it
should be used second-line [1,33].
Conclusions
In conclusion despite worldwide increase in the preva-
lence of resistance for complicated UTI, patients with
AUC still exhibit extremely low resistance rates. System-
atic use of rapid urine test could reduce, the amount of
antibiotics prescribed by 10%. Whenever required, antibi-
otics should be chosen exclusively from molecules that
have minimal adverse effects including collateral damages.
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